EyeBio

EyeBio develops a pipeline of novel therapies for retinal and eye diseases.

New York, NY, USA—Founded 2021—Website

£52.0MTotal raised

EyeBio is a clinical stage ophthalmology biotechnology company developing therapies for sight threatening eye diseases. The firm operates across the United States and the United Kingdom.

Founders

David Guyer

Chief Executive Officer and Co-Founder

David serves as chief executive officer and co-founder of EyeBio, following leadership roles at Iveric Bio and Eyetech Pharmaceuticals alongside venture capital experience at SV Life Sciences.

Tony Adamis

Chief Scientific Officer and Co-Founder